Benjamin Rush Institute · Aug 18, 2026
Sally Pipes: "CMS Undermining Next Generation of Medicines"
0Sign in to vote or save
Treating distinct FDA-approved products as though they were the same drug doesn’t merely reinterpret the statute—it weakens the incentives that drive medical progress.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.